Katarina Luptakova
Vermogen: 22 753 $ op 30-06-2026
Vermogen: 22 753 $ op 30-06-2026
Katarina Luptakova worked at Tesaro, Inc. from 2017 to 2020, serving as Senior Medical Director from 2018 to 2020.
From 2020 to 2021, worked at Constellation Pharmaceuticals, Inc. as Vice President-Clinical Development.
From 2022 to 2023, worked at Xilio Therapeutics, Inc. as Senior Vice President-Medical.
Education includes a doctorate from the University of Commenius.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 02-01-2026 | 2.375 ( 0,04% ) | 22 753 $ | 30-06-2026 |
| Bedrijven | Functie | Einde |
|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-10-2021 |
| TESARO INC | Hoofd Techniek/Wetenschap/O&O | 01-04-2020 |
| XILIO THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Tesaro, Inc.
Tesaro, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for cancer patients | Health Technology |
University of Commenius
University of Commenius Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Constellation Pharmaceuticals, Inc.
Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs targeting regulators of epigenetic function | Health Technology |
Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau